News & Trends - Pharmaceuticals

Biogen triumphs over Mylan’s patent challenge

Health Industry Hub | February 10, 2020 |
[Total: 1    Average: 4/5]

Biogen starts the year successfully by winning a patent challenge from Mylan over its multiple sclerosis drug Tecfidera. 

The challenge from Mylan focused on Biogen’s patent on Tecfidera (dimethyl fumarate) which is due to expire in 2028. The dispute was a significant one for Biogen – Tecfidera is its top-selling drug, bringing in $4.43bn in 2019, which was more than 30% of the company’s total revenues.

The Patent Trial and Appeal Board in the US determined that Mylan did not sufficiently demonstrate its claim and dismissed the challenge.

Responding to the ruling, Mylan said that it would investigate all grounds for appeal, with a spokesperson for the company saying that it “strongly disagrees with the decision”.

Although, Biogen has also been facing other challenges in the MS market from Novartis and Roche, it has its own next-generation MS treatment, Vumerity (diroximel fumarate), which was recently FDA approved for the treatment of relapsing forms of the disease. It is not currently registered in Australia.

For comparison, while Tecfidera is a billion-dollar product, the forecast sales of Vumerity are set to reach a modest $111m in 2024.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our proven digital media solutions developed by industry for industry.

You may also like Arrotex boosts respiratory portfolio to $263m with new Boehringer Ingelheim partnership


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Medical

Medical Pharma Biotech MedTech - Medical researchers support interim budget measures and urge longer-term sustainability - Research Australia

Medical researchers support interim budget measures and urge longer-term sustainability

Health Industry Hub | September 28, 2020 |

Medical News: The $700 million bail-out package for university researchers flagged for consideration in the upcoming federal budget would be […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Pfizer Australia backs digital health start-ups, an interview with Country Medical Director Dr Krishan Thiru

Pfizer Australia backs digital health start-ups, an interview with Country Medical Director

Health Industry Hub | September 28, 2020 |

Digital & Innovation: The recent Innovate Health virtual event aimed at navigating commercialisation, accelerating growth and uptake of digital health […]

More


News & Trends - Medical Technology

MedTech News - Documentation of COVID-19 screening fell short of national imperative in Australian hospitals

Documentation of COVID-19 screening fell short of national imperative in Australian hospitals, says new study

Health Industry Hub | September 28, 2020 |

MedTech News: New Australian research on COVID-19 screening of hospital patients during the first wave of the pandemic found that […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche's haemophilia treatment available at no cost to patients

Roche’s haemophilia treatment available at no cost to patients

Health Industry Hub | September 28, 2020 |

Pharma News: The Australian government have agreed to fund a new treatment for haemophilia patients, through the national blood arrangements. […]

More